DE50311397D1 - Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren - Google Patents

Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren

Info

Publication number
DE50311397D1
DE50311397D1 DE50311397T DE50311397T DE50311397D1 DE 50311397 D1 DE50311397 D1 DE 50311397D1 DE 50311397 T DE50311397 T DE 50311397T DE 50311397 T DE50311397 T DE 50311397T DE 50311397 D1 DE50311397 D1 DE 50311397D1
Authority
DE
Germany
Prior art keywords
receptor tyrosine
tyrosine kinases
heterocyclically substituted
kinases inhibitors
substituted indolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50311397T
Other languages
German (de)
English (en)
Inventor
Joerg Kley
Armin Heckel
Frank Hilberg
Gerald Juergen Roth
Thorsten Lehmann-Lintz
Ralf R Lotz
Ulrike Tontsch-Grunt
Meel Jacobus C Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002142350 external-priority patent/DE10242350A1/de
Priority claimed from DE10252969A external-priority patent/DE10252969A1/de
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE50311397T priority Critical patent/DE50311397D1/de
Application granted granted Critical
Publication of DE50311397D1 publication Critical patent/DE50311397D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE50311397T 2002-09-12 2003-09-09 Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren Expired - Lifetime DE50311397D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50311397T DE50311397D1 (de) 2002-09-12 2003-09-09 Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2002142350 DE10242350A1 (de) 2002-09-12 2002-09-12 Heterocyclisch substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10252969A DE10252969A1 (de) 2002-11-14 2002-11-14 Heterocyclisch substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2003/009978 WO2004026829A2 (de) 2002-09-12 2003-09-09 Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
DE50311397T DE50311397D1 (de) 2002-09-12 2003-09-09 Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren

Publications (1)

Publication Number Publication Date
DE50311397D1 true DE50311397D1 (de) 2009-05-20

Family

ID=32031471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE50311397T Expired - Lifetime DE50311397D1 (de) 2002-09-12 2003-09-09 Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren

Country Status (12)

Country Link
US (1) US7148249B2 (https=)
EP (1) EP1551830B1 (https=)
JP (1) JP2006501273A (https=)
AR (1) AR041194A1 (https=)
AT (1) ATE427947T1 (https=)
AU (1) AU2003273842A1 (https=)
CA (1) CA2498781A1 (https=)
DE (1) DE50311397D1 (https=)
ES (1) ES2324710T3 (https=)
PE (1) PE20041080A1 (https=)
TW (1) TW200407125A (https=)
WO (1) WO2004026829A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
KR100629713B1 (ko) * 2004-04-10 2006-09-29 (주)아모레퍼시픽 펜타에리스리톨 유도체와 이의 제조방법, 및 이를포함하는 액정베이스
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
JP2010502741A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
EP2235004A4 (en) * 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ME02273B (me) * 2008-06-06 2016-02-20 Boehringer Ingelheim Int Farmaceutska kombinacija
AR072538A1 (es) * 2008-07-29 2010-09-01 Boehringer Ingelheim Int Derivados de indolinonas, composiciones farmacéuticas y usos
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
CN103848814B (zh) * 2012-12-06 2016-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的取代吲哚满酮衍生物
WO2014086102A1 (zh) * 2012-12-06 2014-06-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
EP3012248B1 (en) * 2013-06-20 2019-09-11 Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
CN112174943A (zh) * 2019-07-03 2021-01-05 四川大学 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010216A2 (en) * 1998-09-25 2002-04-30 Boehringer Ingelheim Pharma New substituted indolinones, their preparation and their use as medicaments
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2004026829A2 (de) 2004-04-01
EP1551830B1 (de) 2009-04-08
WO2004026829A3 (de) 2004-10-07
US20050054710A1 (en) 2005-03-10
PE20041080A1 (es) 2005-02-17
CA2498781A1 (en) 2004-04-01
TW200407125A (en) 2004-05-16
AU2003273842A1 (en) 2004-04-08
US7148249B2 (en) 2006-12-12
JP2006501273A (ja) 2006-01-12
EP1551830A2 (de) 2005-07-13
ES2324710T3 (es) 2009-08-13
AR041194A1 (es) 2005-05-04
AU2003273842A8 (en) 2004-04-08
ATE427947T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE50311397D1 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE430754T1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
DE60121595D1 (de) Mannich base prodrugs von 3-(pyrrol-2-ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren
ATE316527T1 (de) Substituierte indolinone als tyrosinkinase inhibitoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
DE60324767D1 (de) Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten
ATE440095T1 (de) Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist
ATE280757T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE367381T1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE50310122D1 (de) 4-substituierte 1-aminocyclohexan-derivate zur verwendung als orl1-rezeptor- und mu-opiat-rezeptor-liganden
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
ATE399768T1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE602004022458D1 (de) Pyrazolderivate und ihre verwendung als orexin-rezeptor-antagonisten
DE60320457D1 (de) Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
DE60322551D1 (de) 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena

Legal Events

Date Code Title Description
8364 No opposition during term of opposition